Alembic Pharma gets USFDA’s tentative nod for Olopatadine Hydrochloride Ophthalmic Solution

04 Dec 2024 Evaluate

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief Ophthalmic Solution, 0.7%, of Alcon Laboratories, Inc. (Alcon) NDA - 206276. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) has an estimated market size of $22 million for twelve months ending September 2024 according to IQVIA. The company has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company.


Alembic Pharma Share Price

853.80 -3.45 (-0.40%)
26-Dec-2025 15:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.00
Dr. Reddys Lab 1268.00
Cipla 1503.00
Zydus Lifesciences 911.95
Lupin 2101.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×